Adverse Drug Reaction Reporting and Monitoring is Prime Need in India

Adverse Drug Reaction Reporting and Monitoring is Prime Need in India

​​Indubhai Patel College of Pharmacy and Research Centre, managed by Sanskruti Sanraksha Charitable Trust organised 2-day Conference on ‘Adverse Drug Reaction Reporting and Monitoring is Prime Need in India at Dharmaj near Vadodara. Around 140 delegates participated in the event. 30 Posters were presented in the Conference. DST & GUJCOST sponsored the conference.

Prof.(Dr) Navin Sheth, Vice Chancellor of Gujarat Technological University (GTU) and Member, Board of Advisers of Accuprec Research Labs inaugurated the conference. He put emphasis on mentoring pharma students in such a way that interest should be created by motivating them. He said that Adverse Drug Reaction (ADR) Monitoring & Reporting is not being done properly. There is need of such reporting system especially in Rural area. Now Online reporting is also possible as pharma manufacturers have to create special mechanism including exclusive email for ADR.

Dr. Manish Rachchh, Director & CEO of Accuprec Research Labs, Dr. Mira Desai, Professor & Head of Department in Pharmacology Department of B.J.Medical College, Ahmedabad, Dr. Barna Ganguly from Pramukhswami Medical College, Karamsad, Dr. Rohan Parikh from Akansha Hospital, Anand, Dr. Parloop Bhatt from L.M. College of Pharmacy and Dr. B.M. Sattigeri from Sumandeep Vidyapith were among the expert panel of the Conference. Dr. Nehal Shah, Principal of the college welcomed all. Dr. R.K.Sinha, Principal of SGPIP Physiotherapy college was the Guest of Honour in the 2nd day event.

Experts discussed various topics including role of Health Care professionals in ADR monitoring, current trends of ADR monitoring system in India, ADR reporting system is prime need in India, pharmacovigilance and data management challenges in ADR reporting etc. They expressed opinion that Adverse Drug Reactions monitoring is a process of continuously monitoring of undesirable effect suspected to be associated with use of medicinal products. It is mandatory for pharmaceutical manufacturers or product registrants to monitor their products in the market and report any suspected undesirable effects to TFDA.

ADVICE ABOUT REPORTING

• Report adverse experiences with medications
• Report serious adverse reactions. A reaction is serious when the patient outcome is:

1. death
2. life-threatening (real risk of dying)
3. hospitalization (initial or prolonged)
4. disability (significant, persistent or permanent
5. congenital anomaly
6. required intervention to prevent permanent impairment or damage

Who can report:

Any health care professional (Doctors including Dentists, Nurses and Pharmacists)

Where to report:

• Please return the completed form to the nearest
• Adverse drug reaction Monitoring Centre (AMC) or to National Coordinating Centre
• A list of nationwide AMCs is available at: http://cdsco.nic.in/pharmacovigilance.htm

http://www.cdsco.nic.in/writereaddata/ADR%20form%20PvPI.pdf